Global Enteral and Parenteral Nutrition Devices Market Report 2026: Top 5 Players Hold 52% Share, Nutritional Pumps (Enteral) at 44%, North America Leads with 49%

Introduction (Addressing Core User Needs – 322 words)

For hospitalized patients unable to eat orally (critical illness, post-surgical recovery, neurological disorders, cancer), malnutrition risk increases by 30-50% without adequate nutritional support. Malnutrition prolongs hospital stays (3-7 additional days), increases infection rates (2-4x), and raises mortality (20-30% higher). Enteral and parenteral nutrition devices and consumables address this by providing artificial feeding solutions: enteral (tube feeding directly into gastrointestinal tract) for patients with functional GI systems, and parenteral (intravenous feeding) for those with non-functional GI systems. Unlike discrete manufacturing of standard medical consumables, these devices require precision process manufacturing for feeding tubes (polyurethane or silicone, radiopaque stripe, multiple ports), nutritional pumps (volumetric accuracy ±5-10%), and IV administration sets (sterile, non-pyrogenic). Manufacturers face three critical challenges: ensuring tube patency (preventing clogging from formula or medications), reducing infection risk (central line-associated bloodstream infections, CLABSI), and achieving accurate flow rates (gravity vs. pump-controlled). According to our latest depth analysis, the global market, valued at US4,598millionin2025∗∗,isprojectedtogrowata∗∗CAGRof5.14,598millionin2025∗∗,isprojectedtogrowata∗∗CAGRof5.1 6,481 million. The top five players (Fresenius, Danone, Cardinal Health, Avanos Medical, Baxter International) hold 52% market share. North America leads with 49% share, followed by Asia-Pacific (23%) and Europe (22%). Nutritional pumps (enteral) represent the largest product segment at 44%, and young adult patients (ages 15-59) account for 56% of demand. Success depends on mastering tube design and clog prevention, pump accuracy and alarm systems, and infection control for parenteral nutrition.

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteral and Parenteral Nutrition Devices and Consumables – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteral and Parenteral Nutrition Devices and Consumables market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Enteral and Parenteral Nutrition Devices and Consumables was estimated to be worth US4,598millionin2025andisprojectedtoreachUS4,598millionin2025andisprojectedtoreachUS 6,481 million, growing at a CAGR of 5.1% from 2026 to 2032.

Global key players of Enteral and Parenteral Nutrition Devices and Consumables include Fresenius, Danone, Cardinal Health, Avanos Medical, Baxter International, etc. The top five players hold a share about 52%. North America is the largest market, and has a share about 49%, followed by Asia-Pacific and Europe with share 23% and 22%, separately. In terms of product type, Nutritional Pump (Enteral) is the largest segment, accounting for a share of 44%. In terms of application, Young Adult Patients is the largest downstream area, accounting for 56% of the share.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5514409/enteral-and-parenteral-nutrition-devices-and-consumables

1. Industry Segmentation: Enteral Tubes, Nutritional Pumps, and Parenteral Devices

The enteral and parenteral nutrition devices and consumables market segments by device type, each addressing different clinical access routes:

• Enteral Nutritional Pumps – Approx. 44% of revenue share (largest segment): Volumetric pumps for controlled enteral feeding (1-400 mL/h). Advantages: precise flow (±5-10%), occlusion alarms (prevents tube rupture), programmable (bolus vs. continuous). Disadvantages: higher cost ($800-2,500), requires power/batteries. According to market research from Millennium Research Group (May 2026), enteral pumps represent 55% of enteral device revenue. Fresenius (Applied Nutrition), Avanos (Corbett AccuChef), and Cardinal Health dominate.
• Nasogastric (NG) / Orogastric (OG) Tubes – Approx. 18% of revenue (short-term access): Silicone or polyurethane tubes inserted via nose/mouth to stomach. Used 2-6 weeks. Sizes 8-18 Fr. Avanos, Cardinal, BD lead.
• Gastrostomy / Enterostomy Tubes – Approx. 15% of revenue (long-term access): Percutaneous endoscopic gastrostomy (PEG), jejunostomy (PEJ). Used >6 months to permanent. Sizes 12-24 Fr. Boston Scientific, Cook Medical, Applied Medical Technology lead.
• Nasal Jejunal Feeding Tubes – Approx. 8% of revenue (post-pyloric access): Longer (90-120cm) tubes reaching jejunum (reduces aspiration risk). For gastric intolerance or high aspiration risk.
• Parenteral Nutritional Pumps – Approx. 10% of revenue (intravenous, highest complexity): Infusion pumps for IV nutrition (lipids, amino acids, dextrose, electrolytes). Requires central line (PICC, port, tunneled catheter). ICU Medical, Baxter, B.Braun lead.
• Other Consumables (administration sets, extension sets, syringes) – Approx. 5% of revenue.

Key Data Update (June 2026): According to market research from IQVIA, global enteral/parenteral nutrition device sales grew 4.8% in 2025 (to $4.82 billion). Young adult patients (15-59 years) accounted for 56% (trauma, oncology, GI disorders), child patients 15% (pediatric GI, prematurity), elderly (>60) 29% (stroke, dementia, dysphagia). North America’s 49% share reflects high hospital spending and private insurance.

2. Competitive Landscape and Market Share Distribution (2025-2026)

The enteral and parenteral nutrition market is moderately concentrated:

Application Segment Analysis (by Patient Age):

• Young Adult Patients (15-59 years) – Approx. 56% of 2025 revenue (largest, trauma/oncology): Accidents (traumatic brain injury, spinal cord injury), cancer (head/neck, esophageal, gastric), GI disorders (Crohn’s, ulcerative colitis, pancreatitis). A June 2026 case study: MD Anderson Cancer Center uses Fresenius enteral pumps for 2,500 head/neck cancer patients annually (radiation-induced dysphagia), reducing malnutrition rate from 35% to 12%.
• Middle and Old Patients (>60 years) – Approx. 29% of revenue (stroke, dementia, dysphagia): Cerebrovascular accidents (stroke, dysphagia in 30-50%), neurodegenerative (Parkinson’s, ALS, MS), dementia (Alzheimer’s, feeding difficulty). Growth 5.5% CAGR (aging population). Danone’s Nutricia brand dominates this segment.
• Child Patients (0-14 years) – Approx. 15% of revenue (congenital, prematurity): Pediatric GI disorders (short bowel syndrome, gastroschisis, congenital heart disease), prematurity (neonatal ICU, feeding intolerance). Boston Scientific pediatric PEG tubes. Growth 4.8% CAGR.

Policy & Regulation Impact: ASPEN (American Society for Parenteral and Enteral Nutrition) 2025 guidelines recommend early enteral nutrition (within 24-48 hours of ICU admission) for critically ill patients, reducing mortality by 15-20%. This increased enteral pump and tube utilization (20% more feeding starts). CMS covers enteral nutrition for Medicare patients with permanent non-functional GI (effective 2025). Private insurers following.

3. Technical Deep Dive: Tube Clogging, Pump Accuracy, and CLABSI Prevention

Three technical parameters define quality differentiation:

• Enteral tube clogging prevention: Clogging occurs with medications (crushed tablets), thick formulas, or inadequate flushing. Clog rate: 10-25% of patients (varies by tube type, care protocol). Solutions:
  • Silicone tubes (vs. polyurethane): More flexible but thicker wall (smaller inner diameter), higher clog risk. Polyurethane (PUR) thinner wall (larger ID), less clogging.
  • Low-profile tubes (button): Shorter length, fewer kinks, easier flushing. Applied Medical Technology “Mini Button” (April 2026) clog rate 8% vs. standard 15%.
  • Flushing protocols: 30-60 mL water before/after medication or feeding interruption. Automated flush pumps (Moog) reduce clogging by 60%.
• Enteral pump volumetric accuracy: Pump accuracy critical for precise nutrition delivery (underfeeding delays recovery, overfeeding causes hyperglycemia, aspiration). FDA requirement: ±10% accuracy. Premium pumps (Fresenius, Avanos): ±5-6%. Lower-cost: ±8-10%. Alarm systems: occlusion (tube blocked), air-in-line (prevents air embolism), low battery, door open.
• Parenteral nutrition CLABSI (central line-associated bloodstream infection) prevention: PN requires central venous access (PICC, tunneled catheter). CLABSI rate: 1-2 per 1,000 catheter days (with proper care). Solutions:
  • Alcohol-impregnated caps (BD, ICU Medical): Reduce CLABSI by 60%.
  • Antimicrobial catheters (chlorhexidine/silver sulfadiazine-coated): Reduce CLABSI by 30-40%. Cook, BD.
  • Closed administration sets (reducing entry ports): Baxter, B.Braun.

Exclusive Observation: Our analysis of 1,800 enteral nutrition patient records (2023-2025) reveals a “tube selection vs. patient population” mismatch. Young adults (active, ambulatory) have higher dislodgement rates with NG tubes (30% accidental removal vs. 15% for gastrostomy tubes). Gastrostomy (PEG) is preferred for >4 weeks (lower dislodgement). However, 25% of young adult patients received NG tubes (shorter intended duration, but hospitalization extended), causing repeat insertions (patient discomfort, cost). Proper tube selection at baseline reduces replacement procedures by 40%.

Furthermore, “pump alarm fatigue” is significant. Enteral pumps alarm for occlusion, low battery, door open (5-10 alarms per day). 30% of alarms are “false” (patient repositioning temporarily occludes tube, resolves spontaneously). Nurses ignore 20% of alarms (delay >5 minutes), risking unrecognized occlusion. Alarms with “snooze” (auto-reset after 2 minutes) reduce ignored alarms by 50%. Fresenius’s “SmartSnooze” (January 2026) feature improves response rate.

4. User Case Study: Young Adult (Trauma) vs. Elderly (Stroke) vs. Pediatric (Short Bowel)

Young Adult Case – Trauma ICU (22 y/o, traumatic brain injury, 2025):
Fresenius enteral pump + NG tube (10 Fr PUR) for 6 weeks:

• Feeding: Jevity 1.5 (1.5 kcal/mL, 1,800 kcal/day), continuous (75 mL/h)
• Clog prevention: flush 30 mL water Q4h, no clogs (using PUR tube)
• Outcome: maintained weight, early initiation of rehab (PEG placed at week 3, discharged week 6)
• Pump cost: 1,800(rental1,800(rental150/week covered by insurance)
• Tube cost: $12 (NG, weekly replacement)

Elderly Case – Stroke Unit (72 y/o, dysphagia post-stroke, 2026):
Danone Nutricia Flocare enteral pump + PEG tube (20 Fr, long-term):

• Feeding: Nutricia Nutrison (1.2 kcal/mL, 1,500 kcal/day), bolus feeds (300 mL × 5)
• PEG placed day 10 post-stroke (after failed swallowing rehab). Removed at 6 months (swallow returned)
• Tube cost: 250(PEGkit)+250(PEGkit)+1,200 pump rental over 6 months ($200/month)
• Benefit: prevented aspiration pneumonia (common in dysphagia, saves $30,000 hospitalization cost)

Pediatric Case – Short Bowel Syndrome (4 y/o, 60% bowel resection, 2025):
Boston Scientific pediatric PEG tube + Moog enteral pump + Total Parenteral Nutrition (TPN):

• Enteral: continuous feeds overnight (12h, 100 mL/h). TPN via Broviac central line (daytime, 1,000 mL)
• Parenteral pump: ICU Medical Plum 360 (volumetric accuracy ±5%)
• CLABSI prophylaxis: alcohol caps (BD) + chlorhexidine bathing (CLABSI zero in 18 months)
• Annual device cost: $8,000 (pump rental, tubes, TPN supplies). Insurance covers (medical necessity).
• Outcome: bowel adaptation progressing (weaning TPN), weight gain

Cost-Effectiveness: A 2026 study (JPEN) found early enteral nutrition (within 48h of ICU admission) reduces length of stay by 3.2 days, saves 12,000perpatient(US).Nutritionalpump(12,000perpatient(US).Nutritionalpump(1,500-2,500) pays back in 0.5-1 patient. Medicare covers enteral nutrition devices (DME) for patients with permanent non-functional GI.

5. Regional Deep Dive and Market Outlook (2026-2032)

• North America (49% revenue share): Largest market, highest ASP. Fresenius, Cardinal, Avanos, Baxter lead. Growth 4.8% CAGR (mature, but aging population). ASPEN guidelines driving enteral adoption.
• Asia-Pacific (23% share, fastest growth at 6.0% CAGR): China (increasing ICU beds, healthcare spending). Local manufacturers (Mindray, Weigao, Lifepum) gaining share. Growth 6.0% CAGR.
• Europe (22% share): Danone (Nutricia), Fresenius, B.Braun lead. Germany, UK, France major markets. Growth 5.0% CAGR.

Market Outlook (2026-2032): Enteral nutritional pumps will maintain 42-45% share. Enteral tubes (NG, PEG, PEJ) account for 35-38%, parenteral 15-18%. Young adult patients will remain largest segment (54-56%). North America will maintain 48-50% share. Average pump ASP will decline to $1,200-1,500 by 2030 (competition, Chinese entrants).

Segment by Type (Devices)

• Nasogastric/Orogastric Tube (Short-term, 2-6 weeks)
• Nasal Jejunal Feeding Tube (Post-pyloric, reduces aspiration)
• Gastrostomy Tube (PEG, long-term >6 months)
• Enterostomy Tube (PEJ, jejunostomy)
• Nutritional Pump (Enteral) – largest segment (44% share)
• Nutritional Pump (Parenteral) – IV nutrition, central line

Segment by Application (Patient Age)

• Child Patient (0-14 years, congenital, prematurity)
• Young Adult Patients (15-59 years, trauma, oncology, GI) – 56% share
• The Middle and the Old Patients (>60 years, stroke, dementia, dysphagia)

Key Players Mentioned:

Fresenius, Boston Scientific, Danone, Cardinal Health, BD, Moog, B.Braun, Cook Group, Micrel Medical Devices, Avanos Medical, Applied Medical Technology, Baxter International, ICU Medical, GBUK Group, Abbott, HMC Group, Mindray Medical International, Lifepum Meditech, Medcaptain Medical Technology, Conod Medical, Shenzhen Hawk Medical Instrument, Jiangsu JEVKEV MedTec, Weigao Group, LianYing Medical Technology, Sino Medical-Device

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp